NCT02511132 2022-12-22A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's SarcomaGradalis, Inc.Phase 2 Completed22 enrolled 13 charts